<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35094672</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2222-1751</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Emerging microbes &amp; infections</Title>
          <ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques.</ArticleTitle>
        <Pagination>
          <StartPage>438</StartPage>
          <EndPage>441</EndPage>
          <MedlinePgn>438-441</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2030199</ELocationID>
        <Abstract>
          <AbstractText>Mucosal immunity provides a potential for preventing initial infection and stopping subsequent transmission of SARS-CoV-2. Here, we examined the safety and immunogenicity of a replication-defective adenovirus type-5 vectored vaccine (Ad5-nCov) encoding SARS-CoV-2 spike protein delivered by nebulization inhalation in rhesus macaques. The vaccine-associated clinical pathology and toxicity were not observed in the NHP model. The extensive safety study indicated that Ad5-nCoV was mainly confined to the organs related to respiratory system and was rapidly cleared away from the system. Our results showed that Ad5-nCoV delivered by inhalation robustly elicited both systematic and mucosal immune responses against SARS-nCoV-2 and variants. Thus, Ad5-nCoV inhalation may provide an effective, safe and non-invasive vaccination strategy for the control of SARS-CoV-2.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>CanSino Biologics, Tianjin, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Shipo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yi</LastName>
            <ForeName>Linan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>CanSino Biologics, Tianjin, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Shaodan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>CanSino Biologics, Tianjin, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Fan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>CanSino Biologics, Tianjin, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Si</LastName>
            <ForeName>Weixue</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>CanSino Biologics, Tianjin, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Lihua</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>CanSino Biologics, Tianjin, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Emerg Microbes Infect</MedlineTA>
        <NlmUniqueID>101594885</NlmUniqueID>
        <ISSNLinking>2222-1751</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018928" MajorTopicYN="Y">Immunity, Mucosal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2 vaccine</Keyword>
        <Keyword MajorTopicYN="N">aerosol</Keyword>
        <Keyword MajorTopicYN="N">immunoglobulin A</Keyword>
        <Keyword MajorTopicYN="N">inhalation</Keyword>
        <Keyword MajorTopicYN="N">mucosal immunity</Keyword>
        <Keyword MajorTopicYN="N">safety</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35094672</ArticleId>
        <ArticleId IdType="pmc">PMC8803102</ArticleId>
        <ArticleId IdType="doi">10.1080/22221751.2022.2030199</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ndwandwe D, Wiysonge CS.. 
COVID-19 vaccines. Curr Opin Immunol. 2021.  ;71:111–116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8272971</ArticleId>
            <ArticleId IdType="pubmed">34330017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Shah SM, Alsaab HO, Rawas-Qalaji MM, et al. . 
A review on current COVID-19 vaccines and evaluation of particulate vaccine delivery systems. Vaccines (Basel). 2021;9(10).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8540464</ArticleId>
            <ArticleId IdType="pubmed">34696194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmann M, Kleine-Weber H, Schroeder S, et al. . 
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. e8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7102627</ArticleId>
            <ArticleId IdType="pubmed">32142651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lukassen S, Chua RL, Trefzer T, et al. . 
SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J
2020;39(10):e105114. doi:10.15252/embj.20105114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.20105114</ArticleId>
            <ArticleId IdType="pmc">PMC7232010</ArticleId>
            <ArticleId IdType="pubmed">32246845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Ku M-W, Bourgine M, Authié P, et al. . 
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host Microbe. 2021;29(2):236–249. e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7738935</ArticleId>
            <ArticleId IdType="pubmed">33357418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassan AO, Kafai NM, Dmitriev IP, et al. . 
A single-dose intranasal Chad vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020;183(1):169–184. e13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7437481</ArticleId>
            <ArticleId IdType="pubmed">32931734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng L, Wang Q, Shan C, et al. . 
An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun. 2020;11(1):4207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7442803</ArticleId>
            <ArticleId IdType="pubmed">32826924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu F-C, Li Y-H, Guan X-H, et al. . 
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7255193</ArticleId>
            <ArticleId IdType="pubmed">32450106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halperin, S. A.
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-cont. Lancet (2021). doi:10.1016/s0140-6736(21)02753-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(21)02753-7</ArticleId>
            <ArticleId IdType="pmc">PMC8700283</ArticleId>
            <ArticleId IdType="pubmed">34953526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie J, Li Q, Wu J, et al. . 
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680–686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7144318</ArticleId>
            <ArticleId IdType="pubmed">32207377</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
